|
IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial. |
| |
|
Employment - BioNTech; GANYMED Pharmaceuticals (I) |
Leadership - BioNTech; GANYMED Pharmaceuticals (I) |
Stock and Other Ownership Interests - BioNTech; GANYMED Pharmaceuticals (I) |
Consulting or Advisory Role - GANYMED Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - BioNTech; BioNTech (I); GANYMED Pharmaceuticals; GANYMED Pharmaceuticals (I) |
| |
|
Honoraria - Lilly; Roche Pharma AG |
Consulting or Advisory Role - Lilly; Roche Pharma AG |
Research Funding - Celgene; Novartis; Roche Pharma AG; Sanofi |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Celgene; Novartis; Roche Pharma AG |
| |
|
Research Funding - Fresenius Biotech; GlaxoSmithKline; Merck |
Travel, Accommodations, Expenses - Lilly; Merck; Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; Roche Pharma AG |
Consulting or Advisory Role - Lilly; Roche Pharma AG |
Research Funding - GlaxoSmithKline (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Novartis |
| |
|
Employment - GANYMED Pharmaceuticals |
| |
|
Employment - GANYMED Pharmaceuticals |
| |
|
No Relationships to Disclose |